STOCK TITAN

FENNEC PHARMACEUTICALS (FENC) SEC Filings

FENC NASDAQ

Fennec Pharmaceuticals Inc. filings document formal disclosures for its commercial specialty pharmaceutical business, PEDMARK® product updates, and Nasdaq-listed common shares. Recent Form 8-K reports cover financial results, scientific presentations and investigator-sponsored studies involving sodium thiosulfate injection, and a license agreement resolving litigation tied to a proposed generic version of PEDMARK.

The company’s proxy materials cover director elections, board composition, executive compensation, equity awards, and shareholder voting matters. Other current reports disclose governance changes, registered common shares with no par value, and exhibits furnished with press releases concerning business, clinical, and product-related developments.

Rhea-AI Summary

Fennec Pharmaceuticals Inc. (FENC) director Marco Maria Brughera exercised options to acquire 20,000 common shares at $2.11 per share on November 13, 2026, then sold 20,000 shares at $12.00 per share. Both transactions were made under a Rule 10b5-1 plan adopted June 16, 2026.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
insider
-
Rhea-AI Summary

An amendment concerning Fennec Pharmaceuticals Inc. (FENC) lists Solas Capital Management, LLC and its portfolio manager, Frederick Tucker Golden, as persons who may be deemed beneficial owners of 1,433,282 common shares each, or 4.1% of the class. Both report shared voting and dispositive power over the shares, with no sole voting or dispositive power. Solas serves as investment manager to one private fund and sub-adviser to another; both funds disclaim beneficial ownership of the reported securities.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
ownership
-
Rhea-AI Summary

Fennec Pharmaceuticals Inc. (FENC) was the subject of an amended beneficial-ownership report by Sonic Fund II, L.P., Sonic GP LLC and Lawrence Kam. As of September 30, 2026, Kam may be deemed to beneficially own 1,592,559 shares, or 4.5%. The Fund directly holds 1,457,357 shares, and Sonic GP LLC may be deemed to own those shares through its role as the Fund’s general partner; Kam may be deemed to own them through his role as the GP’s managing member. Kam directly holds 135,202 shares with sole voting and dispositive power. Fennec had 35,305,117 shares outstanding as of November 10, 2026, the basis cited for the ownership percentages.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
ownership
Rhea-AI Summary

Fennec Pharmaceuticals Inc. (FENC) director Marco Brughera, who signed as Marco Maria Brughera, gave notice of a proposed sale of 20,000 common shares, with an aggregate market value of $240,000.00 and an approximate sale date of November 13, 2026. The shares were acquired from the issuer on November 13, 2026 through a stock option exercise, with cash listed as the payment method. The notice reports 35,305,117 common shares outstanding and a September 15, 2026 sale of 15,545 common shares for gross proceeds of $160,069.97 during the prior three months. It lists June 16, 2026 as the plan adoption or instruction date, if relying on Rule 10b5-1.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
other
-
Rhea-AI Summary

Fennec Pharmaceuticals Inc. (FENC) reported third-quarter 2026 revenue of $19.608 million, including $19.425 million in net PEDMARK sales, versus $12.462 million in third-quarter 2025. Net income was $4.640 million, versus a $638,000 loss; diluted earnings per share were $0.12 versus a $0.02 loss. For the first nine months, revenue was $52.590 million and net income was $6.814 million, compared with $30.865 million in revenue and a $4.954 million loss in 2025.

Cash and cash equivalents were $48.684 million at September 30, 2026. Nine-month operating cash flow was $9.111 million, versus $6.511 million used in 2025. Fennec believes existing cash and expected operating revenues will be sufficient to fund its operating plan for at least the next twelve months from issuance of the statements.

In the open-label, single-arm Japanese STS-J01 study, American Speech-Language-Hearing Association-defined hearing loss occurred in 6 of 25 patients (24.0%), versus a 56.4% historical benchmark (p=0.001). Objective tumor responses occurred in 23 of 24 evaluable patients (95.8%), and no serious adverse event was attributed to PEDMARK. Fennec is pursuing Japanese registration and evaluating partnering or licensing opportunities; discussions with potential partners and regulators are ongoing.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.61%
Tags
quarterly report
-
Rhea-AI Summary

Fennec Pharmaceuticals Inc. (FENC) Chief Commercial Officer Terry L. Evans reported acquiring 168 Common Shares on October 31, 2026. The shares were released from restriction from shares awarded March 28, 2025. Evans reported holding 24,181 Common Shares directly following the transaction; this was an award-related release, not a market purchase.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.52%
Tags
insider
Rhea-AI Summary

Fennec Pharmaceuticals Inc. Chief Medical Officer Pierre Sargis Sayad reported the release from restriction of 168 common shares on October 31, 2026; the shares came from an award made March 28, 2025. His reported direct holdings following the transaction were 13,701 shares.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.52%
Tags
insider
-
Rhea-AI Summary

Fennec Pharmaceuticals Inc. (FENC) CEO Jeffrey S. Hackman acquired 1,159 common shares on October 31, 2026, when shares from an award made March 28, 2025 were released from restriction. The reported acquisition reflects an award-related release, not an open-market purchase. Hackman directly held 70,844 common shares following the transaction.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.52%
Tags
insider
-
Rhea-AI Summary

Fennec Pharmaceuticals Chief Strategy Officer Christiana Marie Cioffi acquired 156 common shares on October 31, 2026, when previously awarded shares were released from restriction. Her reported direct holdings after the transaction were 28,902 common shares. This was a release of previously awarded shares, rather than a separately described market purchase.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.52%
Tags
insider
Rhea-AI Summary

Fennec Pharmaceuticals Inc. Chief Financial Officer Robert Andrade reported acquiring 1,703 common shares on October 31, 2026, through release from restriction of shares awarded on May 16, 2024, and March 28, 2025. The shares were held directly, bringing his reported direct holdings to 248,558 common shares after the transaction.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.52%
Tags
insider

FAQ

How many FENNEC PHARMACEUTICALS (FENC) SEC filings are available on StockTitan?

StockTitan tracks 149 SEC filings for FENNEC PHARMACEUTICALS (FENC), including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and Form 4 insider trading disclosures. Each filing includes AI-generated summaries, impact scoring, and sentiment analysis.

When was the most recent SEC filing for FENNEC PHARMACEUTICALS (FENC)?

The most recent SEC filing for FENNEC PHARMACEUTICALS (FENC) was filed on November 16, 2026.